Trogenix, a clinical-stage precision oncology company, has appointed John Young as Chair and Josh Murray as Non-Executive Director to support its global strategy, commercial growth, and US expansion. John Young brings over 35 years of pharmaceutical leadership, including key roles at Pfizer, while Josh Murray offers deep capital markets and strategic expertise from his experience at Goldman Sachs and Orca Bio. These appointments come as Trogenix advances its AI-enabled Odysseus® platform and progresses its Phase I/II ADePT trial for glioblastoma, positioning the company for its next growth phase and broader cancer treatment applications.
Trogenix's recent leadership appointments provide context for readers. For those following the health sector, here is Pluang's market snapshot as of Nov 10, 2026 12:51 WIB: out of 150 priced US health stocks, 122 rose and 25 fell today. Notable movers include ALMS at USD 6.53 with a 1-day change of +8.29% and 100% buy order activity, RXRX at USD 3.80 up 7.95% also with 100% buy orders, and ERAS at USD 15.55 gaining 7.91%.
Wellington Management Group LLP has notified that it crossed the 5% voting rights threshold in Admiral Group PLC as of November 6, 2026. The group holds a total of 5.01% voting rights through direct shares and financial instruments. This disclosure i...
Pragmatic Semiconductor has appointed Mercedes Johnson as a Non-Executive Director on its Board, effective November 6, 2026. Johnson brings over 40 years of semiconductor industry finance and governance experience, having held senior roles at Broadco...
Equinor ASA has completed the fourth tranche of its 2026 share buyback program, repurchasing a total of 974,300 shares at an average price of NOK 420.35 per share between November 2 and 6, 2026. This brings Equinor's total holdings of its own shares ...
UBS upgraded Morgan Stanley Direct Lending Fund (MSDL) from Neutral to Buy following strong Q3 2026 net investment income of $40.3 million, beating earnings estimates. The fund declared a fourth-quarter dividend and plans fee cuts in 2027 to boost in...
Roche presented new data on its Alzheimer’s disease portfolio at the CTAD 2026 conference, highlighting advances in both pharmaceuticals and diagnostics. Key updates include Phase Ib/IIa data for trontinemab showing rapid amyloid clearance, the start...
